



CONTACT INFORMATION

Parent Company

Scandinavian Medical Solutions A/S Gasværksvej 48, 1.tv., 9000 Aalborg

CVR no.: 39901749

Registered office: Aalborg, Denmark

Report for the period: 01.10.2024 - 30.09.2025

Subsidiaries

Scandinavian Medical Solutions Inc. 221 W Dyer Road, Santa Ana CA 92707, United States

Scandinavian Medical Solutions Sarl 23/25 Avenue Mac-Mahon 75017 Paris, France

Executive Board

Jens Krohn

Jens Hvid Paulsen

Kamilla Malmbæk

Board of Directors

Mille Tram Lux, Chairman of the board Anne Bülow Kaptain, Deputy Chairman Morten Rasmussen, Board member

Certified Adviser

HC Andersen Capital ApS

Bredgade 23B, 2. sal, 1260 København K

Financial Calendar

16 May 2026

Half year Financial Report H1 2025/26

19 November 2026

Annual Financial Report 2025/26

9 December 2026

Annual General Meeting (AGM)



TABLE OF CONTENTS

MANAGEMENT REVIEW

- 4. About Scandinavian Medical Solutions
- 6. Highlights 2024/25
- 6. Outlook 2025/26
- 7. CEO Statement
- 8. Purpose, Vision & Strategy
- 9. Business Model
- 11. Financial developments
- 13. Business developments
- 14. Risks & Uncertainties
- 15. Sustainability & ESG
- 17. Key Figures & Performance Indicators

STATEMENTS

- 18. Statement by the Board of Directors & Executive Board
- 19. Independent Auditor's Report

FINANCIAL STATEMENTS

- 22. Financial Statements
- 28. Notes to Financial Statements & Accounting Policies

"In the coming year, we will focus on maintaining and expanding our market position and drive operational excellence. Supported by a solid foundation, a clear strategic direction, and a diversified business model, we are well positioned to deliver sustainable revenue across all markets."

Jens Paulsen, CEO Scandinavian Medical Solutions A/S





ABOUT SCANDINAVIAN MEDICAL SOLUTIONS

A Global Provider of high-end pre-owned Medical Imaging Equipment

Scandinavian Medical Solutions A/S (SMS) is a Danish growth company specializing in the acquisition, quality check, and global resale of high-quality pre-owned medical imaging systems. The company supplies value-added reseller, and distributors worldwide with advanced diagnostic equipment - including MRI, CT, and PET/CT scanners - from leading manufacturers such as Siemens, GE, Canon and Philips.

Diagnostic imaging uses technologies like X-rays, CT scans, MRI, and ultrasound to create visual representations of the inside of the body to diagnose diseases, monitor treatment, and guide medical interventions. These procedures reveal internal structures and functions that are not visible from the outside, aiding doctors in diagnosing a wide range of conditions and helping to plan treatment.

By extending the lifecycle of premium medical technology, SMS enables healthcare institutions to access state-of-the-art equipment at significantly lower costs compared to new systems. This business model creates value through both economic efficiency and sustainability, supporting the circular economy within the healthcare sector.

History and Growth

Founded in 2018 in Aalborg, Denmark, Scandinavian Medical Solutions was established by industry professionals with deep expertise in medical imaging and international trade. Since its founding, the company has demonstrated strong, profitable growth driven by scalability, efficient asset turnover, and global demand for refurbished high-end equipment, and by combining deep technical expertise with a transparent and customer-centric business model.

In 2021, SMS was listed on Nasdaq First North Growth Market Denmark, providing a solid foundation for continued expansion and visibility among investors. The listing marked an important step in the company's transition from a niche operator to a recognized international player in the pre-owned medical equipment market.

Business Model and Market

Scandinavian Medical Solutions operates as a B2B partner in the global pre-owned medical equipment market within Equipment, Parts and Rental solutions.

Equipment Solutions is the cornerstone of Scandinavian Medical Solutions' operations and the foundation of its international reputation for quality and used high end equipment.





ABOUT SCANDINAVIAN MEDICAL SOLUTIONS



The division focuses on sourcing, quality check, and selling high-end diagnostic imaging systems — primarily MRI, CT, PET/CT, Cath-Lab, and Mammography.

Parts Solutions plays a vital role in maintaining customer relationships across the SMS ecosystem. The division supplies service providers, distributors with high-quality parts, ensuring that hospitals and clinics can maintain and repair imaging systems efficiently and cost-effectively.

Rental Solutions offers hospitals and private clinics across Europe flexible access to imaging systems through short-, medium-, and long-term rental agreements. This enables clinics and hospitals to maintain diagnostic capacity during upgrades, replacements, or peak demand periods — without major upfront investments.

The global market for refurbished medical equipment is growing steadily, driven by cost pressures in healthcare, increasing diagnostic demand, and sustainability considerations

SMS is well-positioned to benefit from these structural trends, leveraging its expertise, supplier relationships, and operational agility to expand its international footprint.

SMS is geographically diversified with North America as the most important market, followed by Asia, Southern Europe and Emerging Markets. Geographical agility is an important pillar of SMS' business model.

The North American market accounts for nearly 50% of the global market for refurbished medical equipment, valued at approximately USD 5bn and expected to grow at in the double digits through 2030.*

*Refurbished Medical Equipment - Global Strategic Business Report, November 2025, Global Industry Analysts, Inc.



KEY HIGHLIGHTS 2024/25

DKK 245m

Revenue

DKK 57m

Gross Profit before other external costs

DKK 11m

8%

Revenue Growth

>30% growth

Parts Solutions and Rental Solutions

"The U.S. market remains strategically important to SMS. Despite uncertainty related to tariffs, demand for high-quality pre-owned imaging systems continues to grow.

Our local setup gives us an advantage when it comes to import, certification, and delivery — allowing us to serve customers faster, more efficiently, and with stronger relationships than ever before."

Jens Krohn, CEO US & Founder Scandinavian Medical Solutions A/S

OUTLOOK 2025/26

We expect 2025/26 to mark a new phase of maintaining and expanding our market position, supported by a strong pipeline, lean operations and disciplined cash flow management.

Financial guidance 2025/26

		Actual
Revenue	220-250	245
EBITDA	11-15	11

Assumptions

While Equipment Solutions remain our main source of revenue, we also anticipate increased contributions from Rental Solutions and Parts Solutions.

Our priority continues to be profitable growth and accelerated cash flow generation in a continued challenging market.

While the US and Southern Europe remain our core markets, we will also pursue opportunities in emerging markets.

We remain confident about our continued market share position in the U.S., supported by our well-established local presence and own organization in California. Over the past year, we have strengthened our relationships with end-users and successfully expanded our customer base within the small and medium-sized segment

While uncertainty regarding tariffs may temporarily affect import activity, the U.S. remains structurally dependent on imports of refurbished medical imaging systems. We therefore expect demand to normalize after a adjustment period.



CEO STATEMENT

Resilience, Adaptability, and Strategic Progress in a Challenging Market

The past financial year has once again demonstrated the resilience and adaptability of Scandinavian Medical Solutions. Supported by powerful megatrends such as ageing populations, growing demand for healthcare, and increasing focus on reuse and circularity, our business model continues to prove its strength — even in a market characterized by uncertainty, tariffs, a weakened dollar to euro exchange rate and slower decision-making.

Despite challenging global conditions, we delivered 8% revenue growth, compared to 2023/24, supported by our broad product portfolio and geographical diversification, which make us less vulnerable to market fluctuations. While Equipment Solutions remained unchanged both Parts Solutions and Rental Solutions achieved growth rates YoY above 30%, confirming the attractiveness of our diversified business model.

The U.S. remains our most important market, followed by Asia and Southern Europe. Over recent years, we have successfully built a solid and self-financed presence in the U.S., where we are now much closer to the end-users of our products. We have strengthened local partnerships, expanded our customer base among small and medium-sized value-added resellers and ensured that all import and certification processes are fully in place — enabling us to handle customs clearance end-to-end.

During the year, we have built up inventory. While this has ensured continuity in supply and enabled us to maintain commitments with key suppliers, it has also resulted in excessive capital tied up in inventory. Our focus for 2025/26 is on optimizing working capital and inventory turnover, supported by a number of commercial excellence initiatives including sharpened market focus, targeted marketing, new market entries, and investments in our sales force.

Operational excellence has been a key priority throughout the year. We have optimized internal processes and introduced cost-saving measures across facilities and volume purchases. Nevertheless, our highly specialized employees remain at

the core of our company — their expertise and dedication are not easily replaceable and form the foundation for our continued growth and customer trust.

We also strengthened our European footprint through the establishment of a French subsidiary in Strasbourg, integrating several experienced specialists who previously worked with SMS as external consultants. This initiative enhances efficiency, reduces dependence on external partners, and strengthens our position in the French-speaking markets, particularly within Rental Solutions.

The first half of the financial year was influenced by geopolitical uncertainty and the risk of trade conflicts, leading to more cautious investment decisions and delays in deliveries. As a result, we adjusted our guidance in March 2025. While the results did not meet our initial expectations, they reflect the broader market environment. Importantly, our U.S. strategy - led by Jens Krohn and his team - remains critical for securing long-term market access and sustainable growth.

Entering the second half, we saw improved profitability and traction on initiated efficiency initiatives. With stronger earnings momentum, leaner operations, and disciplined cash management, we will build a solid foundation for the next phase of our journey.

As we look ahead to 2025/26, we expect a phase of stabilizing to maintain our market position in a continuously challenging market situation. This is supported by a strong pipeline, streamlined operations, and continued focus on cash flow generation. Our mission remains unchanged - to be the most trusted European partner in pre-owned imaging systems, bringing healthcare forward for everyone through Scandinavian quality and global reach.

Jens Hvid Paulsen Chief Executive Officer Scandinavian Medical Solutions A/S



PURPOSE, VISION & STRATEGY

Our Purpose

The future of healthcare is for everyone. Scandinavian Medical Solutions aims to make diagnostic imaging equipment more accessible globally.

Our mission is to increase access to life-saving diagnostics by giving imaging equipment a second life where it matters most. time.

Our Strategy

Scandinavian Medical Solutions is entering the next phase of its development - transitioning from a period of growth and expansion to a phase focused on profitable growth, cash discipline, and operational excellence. The company aims to strengthen its financial resilience and ensure sustainable value creation, while maintaining agility and innovation across its business areas.

Our short-term strategic priorities are to:

- Accelerate cash flow generation: Focus on faster inventory rotation and active working capital management to improve liquidity and capital efficiency.
- Optimize inventory balance: Ensure that SMS holds the right systems and parts in stock to meet customer demand while minimizing tied-up capital.
- Expand the rental fleet: Broaden the Rental Solutions portfolio to offer more flexible, diverse, and high-value options to the European healthcare market.

Our Vision

SMS aims to become the preferred global partner for pre-owned high-end medical imaging systems and to help increase global scan capacity by giving used MRI, CT, and PET/CT systems a second life.

- Diversify revenue streams: Maintain a balanced revenue mix across Equipment Solutions, Rental Solutions, and Parts & Aftersales to reduce dependency and mitigate market risks.
- Pursue emerging markets: Leverage new commercial team members and partnerships to explore opportunities in selected high-potential markets outside core markets in Europe and the US.
- Enhance operational excellence: Continuous optimization of internal processes, quality assurance, and supply chain efficiency to support scalability and reliability across the organization.

Through disciplined execution and continuous improvement, Scandinavian Medical Solutions aims to strengthen its position as a trusted, profitable, and scalable European leader in the global market for pre-owned medical imaging systems - combining Scandinavian quality, global reach, and sustainable growth.



OUR BUSINESS MODEL

Scandinavian Medical Solutions operates as a full-service partner in the global pre-owned medical equipment market.

SMS ensures compliance with international medical standards and offers tailored solutions that match the specific clinical, financial, and logistical needs of each customer.

SMS strive to operate an asset-light and scalable business model. The company purchases pre-owned imaging systems, performs detailed technical inspections and quality checks, and sells them to customers worldwide through its extensive network.

With the aim to ensure efficient capital utilization and short turnover times, SMS is focused on active inventory cycle management.

Based on our focused equipment sales, innovative rental solutions, and dedicated aftersales and parts team, we support healthcare systems in becoming more accessible, efficient, and sustainable.

We operate the business through three business areas, Equipment Solutions, Parts Solutions and Rental Solutions:

Equipment Solutions

Equipment Solutions is the cornerstone of Scandinavian Medical Solutions' operations and the foundation of its international reputation for quality and used high end equipment.

The division focuses on sourcing, quality check, and selling high-end diagnostic imaging systems — primarily MRI, CT, PET/CT, Cath-Lab, and Mammography.

Through long-standing supplier relationships and in-house technical expertise, Equipment Solutions ensures access to premium systems on the market. While the division operates with lower margins and longer sales cycles than other business areas, it remains strategically essential. It secures product availability, anchors SMS's credibility among partners, and acts as the entry point for customer relati-

onships that often extend into Parts and Rental activities.

By maintaining a disciplined approach to sourcing and pricing, Equipment Solutions contributes to both market share growth and a steady inflow of high-quality systems for the rest of the organization.

Supply chain - Equipment Solutions



Parts Solutions

Parts Solutions provides recurring, high-margin revenue and plays a vital role in maintaining customer relationships across the SMS ecosystem.

The division supplies service providers, distributors and hospitals with high-quality parts, ensuring that customers can maintain and repair imaging systems efficiently and cost-effectively.

With inventory hubs in Denmark and the United States, Parts Solutions offers fast global delivery and strong responsiveness — factors that enhance customer satisfaction and retention. The business is characterized by daily transactions, repeat clients, and an increasing contribution to company profitability.

Beyond its standalone performance, Parts Solutions supports Equipment and Rental Solutions by providing spare parts and components for sold or installed systems, thereby reinforcing SMS's position as a full-service and long-term partner in the imaging value chain.

Although the segment requires a steady flow of business to reach significant scale, it holds strong potential as a profitable and recurring revenue stream, strengthening SMS's overall service offering and customer retention.



OUR BUSINESS MODEL

Supply chain - Parts Solutions (new and used) Used parts



Rental Solutions

Rental department strengthens SMS's direct engagement with healthcare providers and is the division with the highest profitability.

The business offers hospitals and private clinics across Europe flexible access to imaging systems through short-, medium-, and long-term rental agreements. This enables healthcare customers and hospitals to maintain diagnostic capacity during upgrades, replacements, or peak demand periods — without major upfront investments

Rental Solutions combines clinical understanding with operational flexibility. Its scalable fleet allows SMS to meet diverse customer needs while achieving strong margins and recurring revenue.

Strategically, Rental Solutions also complement the Equipment and Parts divisions by ensuring an interim solution, while SMS are buying the old equipment from the end user. It demonstrates SMS's ability to move closer to end-users, OEM's, enhance recurring earnings, and strengthen brand presence within the European and United States healthcare market

With a strong combination of profitability and complexity, Rental Solutions is the

division that generates the highest margins within Scandinavian Medical Solutions, though it also carries higher operational and compliance-related costs. Managing medical equipment in clinical environments requires in-depth technical expertise, regulatory awareness, and customer trust - areas where SMS excels.

The rental assets are primarily financed through lease-back financial structure, ensuring flexibility and scalability without significant capital tied up. This approach enables SMS to expand its rental fleet without tying up capital. This financing model supports SMS's strategy of maintaining strong liquidity and capital efficiency in the company.

Supply chain - Rental Solutions







FINANCIAL DEVELOPMENTS

Developments in H2 2024/25

Following a first half marked by geopolitical uncertainty, and cautious customer behavior, we managed to maintain momentum in revenue and return to profitability in the second half.

Revenue of DKK 122.7m in the second half was on par with the first half (H2 2023/24: 124.1m), while EBITDA improved from DKK 0.6m in the first half to DKK 9.9m in the second half (H2: 2023/24: DKK 13.0m).

A primary focus in the second half of the year has been to improve our operational excellence - strengthening execution, refining processes and internal workflows, and enhancing quality assurance.

Developments in 2024/25

Revenue

Revenue increased by 8% to DKK 245m in 2024/25 (2023/24: DKK 227m) slightly above our guidance of DKK 200-240m and in the lower end of initial guidance. Overall, all three business areas have performed well considering volatile market conditions. Both Parts Solutions and Rental Solutions delivered solid results and revenue growth above 30%, while revenue in Equipment Solutions was on par with last year due to due to prolonged decision-making processes and intensified competition in the used imaging equipment market.

Gross Profit before other external costs

Gross profit before other external costs was unchanged DKK 56.7m in 2024/25 (2023/24: DKK 56.8m), despite the growing topline. The flat development is primarily attributable to challenging market conditions, including increased buyer hesitation due to the geopolitical situation, tariff and weakened dollar to euro exchange rate, higher transportation costs, and intensified competition, all of which have negatively impacted earnings. Additionally, the limited availability of scanners for resale and other market conditions have further affected equipment margins.

As a result of challenging market developments, we have made a deliberate decision to honour all existing purchase agreements and to accept lower margins

on equipment sales in the past year aimed at sustaining commercial momentum, while at the same time acting proactively and adapting the organisation and cost structure to a new reality.

As market conditions shifted and prices declined on certain stock items, we act to optimize our inventory, selling slow-moving items and building up stocks of high-turnover items to strengthen our commercial performance, while at the same time acting proactively and adapting the organisation and cost structure to a new reality.

While this has impacted short-term profitability negatively, the approach fully aligns with the Group's long-term strategy of remaining commercially active, competitive, and agile during uncertain periods, ensuring SMS is well-prepared to capitalize on opportunities as market conditions normalize.

As a result of the above-mentioned developments, the gross margin before other external costs decreased from 25.0% last year to 23.1% in 2024/25.

Capacity Costs

Capacity costs increased by 31% to DKK 46.2m in 2024/25 (2023/24: DKK 35.4m), reflecting an increase driven by our U.S. expansion, where both personnel and warehouse capacity were scaled up. The strategic decision to relocate a substantial part of the Group's inventory to the U.S. subsidiary required significant resources while strengthening our operational footprint in the region. This initiative positions the subsidiary for future growth by supporting higher sales activity, faster delivery times, and improved product availability. Furthermore, it aligns with customer purchasing behaviour, which is primarily driven by immediate needs rather than proactive inventory planning. By sourcing and selling more directly within the U.S. market, the Group also reduces exposure to potential future tariffs and trade barriers.

We continuously focus on optimizing our overall capacity costs, including facility expenses such as rent and utilities. Over the past year, we have consolidated our Danish-based warehouses under one roof to strengthen collaboration across departments while also reducing rent and personnel costs. In addition, we



FINANCIAL DEVELOPMENTS

have negotiated new and improved vendor agreements that will generate future savings, particularly on electricity. However, most of our capacity costs are related to our skilled and specialized personnel who are vital for our ability to deliver on our long-term strategy.

EBITDA

EBITDA decreased by 50% to DKK 10.5m in 2024/25 (2023/24: DKK 21.0m) which meets the adjusted guidance and is below initial guidance. The EBITDA is reflecting the above-mentioned developments in gross profit and capacity costs.

The EBITDA result was impacted by changes in exchange rates and especially developments in USD against EUR, as most often systems are purchased in EUR and sold in USD based on an offer and conversion rate given 3-6 months ahead of final payment. It is estimated that changes in EUR/USD had an adverse impact of DKK 1,8m on the EBITDA result in 2024/25.

It is estimated that tariffs have had negative impact of DKK 1.9m on the EBITDA result in 2024/25, as we have been unable and strategically unwilling to fully pass on tariff-related cost increases to customers.

Net Profit

Net profit decreased to DKK 0.2m in 2024/25 (2023/24: DKK 7.8m), reflecting the temporarily elevated capacity costs and adverse effects on gross profit from challenging market conditions.

Balance sheet and cash flow

Investments in tangible fixed assets rose to DKK 20.8m (2023/24: DKK 18.5m), reflecting the Group's focus on targeted, project-specific rental investments. This primarily relates to rental assets under construction that are not yet finalized as per the balance sheet day.

Net working capital increased by DKK 21.1m in 2024/25 (2023/24: Increase of DKK 6.9m). The increase primarily relates to inventories, rising to DKK 109.7m at the end of the financial year (End 2023/24: DKK 84.6m). During the year, we have buildt up

inventory. While this has ensured continuity in supply and enabled us to maintain commitments with key suppliers, it has also resulted in excessive capital tied up in inventory, and our focus is now on optimizing inventory turnover.

Free cash flow before financing amounted to DKK -33.3m (2023/24: DKK -7.7m).

The cash balance at the end of the year amounted to DKK 2.1m (2023/24: DKK 10.8m), while short-term bank debt has increased to DKK 26.5m (2023/24: DKK 0.2m), related to the Company's DKK 30m credit facility.

Going forward, the Group will place greater emphasis on cash flow and ensure a more balanced approach between continued growth and a stronger cash position.





BUSINESS DEVELOPMENTS

Market Development

The global market for pre-owned medical imaging systems remained characterized by volatility in 2024/25, driven by geopolitical uncertainty, varying healthcare budgets, and temporary trade tensions affecting cross-border equipment flows especially between Europe and the United States.

Despite these headwinds, underlying demand for diagnostic capacity continued to grow, supported by ageing populations, increasing scan capacity, and the ongoing replacement of outdated systems in the European market.

In the U.S., the announcement of new import tariffs created temporary hesitation among buyers and longer decision-making processes. However, SMS's established local presence through Scandinavian Medical Solutions Inc. ensured continued access to the market on both the sales, purchasing and rental side and positioned the company to benefit once demand and the market normalizes.

In Europe, market activity remained broadly stable, with strong momentum within Rental Solutions. Meanwhile, selected emerging markets in the Middle East, Asia, and Africa also increasing demand for cost-efficient imaging capacity - representing new opportunities for SMS in the coming years.

Business Highlights

The financial year demonstrated the resilience of SMS's diversified business model. While Equipment Solutions delivered stable revenue despite external challenges, Parts Solutions and Rental Solutions delivered YoY growth above 30%, confirming the strength of the company's multi-segment structure.

Key initiatives during the year included the establishment of a subsidiary in France to enhance local presence, as well as continued strengthening of the U.S. organization, which is now self-financed and operationally independent.

Across the Group, SMS implemented initiatives to improve working-capital efficiency, including tighter inventory management, cost optimization, and new commercial excellence focus.

Despite near-term challenges in the global trading environment, SMS maintained a solid order pipeline, expanded its customer base, and increased the proportion of recurring revenue from parts and rental activities.

Business Segment Insights

Equipment Solutions

Equipment followed historical patterns but at a slower pace. Sales cycles have lengthened, competition is intense, and customer purchasing power has come under pressure.

Parts Solutions

This segment performed strongly, although a significant portion of transit deals involving new spare parts (with lower margins) impacted overall profitability. Nevertheless, sales of in-house harvested parts are gaining momentum and is a strategic focus area.

Rental Solutions

Several new rental projects launched in the first half of 2024/25, and the interest in our MRI and PET/CT rental solutions continue to grow, highlighting the segment's future potential. The business case for the rental solutions is carefully evaluated for every system, and unprofitable systems are turned into equipment sales. Profitability has been adversely impacted by substantial start-up costs, which is not a reflection of the segment's earnings potential. Nearly all rental systems are financed through leasing activities to minimize potential constraints on other parts of the business.



RISKS & UNCERTAINTIES

Market risks

The used medical equipment market is generally sensitive to price fluctuations on new equipment and interest rates developments.

Advances in technology and more efficient production of new imaging equipment could also lead to significant price reductions on new systems. This may narrow the price gap between new and pre-owned equipment, shifting customer preference toward new products. As a result, the market for pre-owned systems could shrink or experience sharp price declines.

Purchasing both new and pre-owned imaging equipment represents a significant investment for most customers and often involves lengthy decision-making processes. In the case of public hospitals and clinics, additional approvals and funding are typically required. For SMS, this means that each potential sale demands substantial time and human resources throughout the preparation and sales process. There is a risk that future sales processes may become more complex or take longer than expected, which could delay revenue recognition.

Scandinavian Medical Solutions attempts to counter market risks by ensuring a diversified product and geographical exposure, by controlling long term commitments, and by ensuring faster rotation of systems in stock.

A temporary downturn in the market is also an opportunity to buy used equipment at low prices. Seizing market opportunities may temporarily result in increased inventory levels.

Import tariff risks

The current tariff environment in the U.S. has created a period of uncertainty in the market for refurbished medical imaging systems. Ongoing discussions about potential tariff changes are causing hesitation among buyers, as customers fear paying inflated prices or being caught by tariff adjustments while equipment is already in transit - a process that can take up to 12 weeks.

Tariffs of up to 15% have been announced on products originally manufactured in Europe or the U.S., including systems from Siemens, Philips, and Canon, which together represent a significant portion of SMS' portfolio. The situation is further complicated by inconsistent customs procedures and interpretation, which adds uncertainty to import processes and temporarily dampens customer appetite.

To mitigate the impact, SMS has focused on increasing local sourcing and refurbishment within the U.S. market. SMS is benefitting from having both import and export licenses and well-functioning custom clearance processes in the US.

SMS has been unable and strategically unwilling to fully pass on tariff-related cost increases to customers, which has strengthened its competitive position and resulted in market share gains. In the event of a prolonged slowdown in U.S. imports, the company remains well-positioned to leverage its local ecosystem by buying and selling within the U.S. and by exporting low- and mid-quality solutions from the U.S. to markets in South and Central America, thereby maintaining revenue diversification and market presence.

Currency risks

As most of SMS's purchases and sales are conducted internationally and in foreign currencies, the company is exposed to exchange rate fluctuations, mainly in USD. Management continuously assesses the need for hedging but has so far found the cost of such arrangements to outweigh.



SUSTAINABILITY & ESG

Scandinavian Medical Solutions has evolved significantly over the years, transforming from a small reseller of diagnostic imaging equipment into a company that operates seamlessly across borders, with substantial growth in both size and revenue.

Our commitment to customers and the entire ecosystem related to pre-owned diagnostic imaging equipment remains at the heart of our business. We go the extra mile to extend the life of scanners and enhance public health worldwide.

Our customers trust us to deliver safe, quality-tested products, and we work tire-lessly to meet and exceed these expectations. Helium Recycling – Implementing New Procedures state, which required removing helium before transportation.

We recognize the impact of our operations on society and are dedicated to creating value through continuous improvement. By embracing sustainability, we aim to generate long-term benefits for our stakeholders and make a meaningful difference in the communities where we operate.

This is the third year that Scandinavian Medical Solutions Group is reporting on three key performance indicators related to our sustainability focus:

- Helium recycling
- Recycling of system components
- Sale of systems or parts to customers in developing countries.

Helium recycling

Helium is an essential cooling element in MRI scanners and a limited global resource. To minimize waste and environmental impact, Scandinavian Medical Solutions has implemented a structured helium recycling process as part of its technical capability.

When an MRI system is sold under certain conditions, the helium is carefully extracted, stored in pressurized recovery tanks, and later reused to refill other MRI systems. This closed-loop approach reduces the need for new helium production, lower transport-related emissions, and supports SMS's commitment to responsible resource management.

Achievements in 2024/25

We successfully recovered 3,605 Liters of helium from six systems during the year (2023/24: 1,000 Liters). This marks a significant improvement compared to last year, driven by better tools and strengthened in-house expertise, which have made our recovery process far more efficient. In essence, the process involves reclaiming helium from systems that no longer need to remain cold - for instance, when they are being transported over long distances or dismantled for parts. The recovered helium is then reused in other systems. The process requires careful handling to avoid contamination, as even small particles can affect the quality of the recovered helium.

Recycling of system components

In our Parts Solutions business, we are focused on expanding our inventory of high-quality used spare parts. Notably, the parts we source for our business are compatible with the most popular used systems, enabling us to support customers who have previously purchased complete systems. Components from systems that have reached their end of life referred to as 'legacy systems' continue to hold value for many customers. By recycling components from these systems, we extend their lifecycle, allowing otherwise discarded parts to be reused, which saves time and money.



SUSTAINABILITY & ESG

Achievements in 2024/25


In the financial year 2024/25, Parts Solutions sold and distributed 16,663 kg of new and used parts to customers worldwide (2023/24: 13,932 kg) of which 9,983 kg were reused spare parts sent to customers for repairs and servicing needs (2023/24: 8,648 kg), equivalent to 60% of all parts sold (62%). This highlights the growth journey of our parts business in recent years. Additionally, Parts Solutions sold four magnets with a combined weight of 16,000 kg to a recycling company.

Systems Sold to Customers in Developing Countries

Scandinavian Medical Solutions' core mission has been to deliver used imaging solutions to customers worldwide. We are incredibly proud of each sale, as each contributes to reusing functional systems and solutions. We know that we are helping to improve imaging capacity in regions with a substantial need. We rarely sell directly to hospitals and clinics; instead, we supply resellers, but we often know the end-destination as our customers increasingly purchase systems to meet specific requirements from end-users.

Achievements/systems sold in 2024/25

In 2024/25 we sold 8 systems (2023/24: 1) to low-income countries and 33 systems to lower-middle income countries (2023/24: 65).





KEY FIGURES & PERFORMANCE INDICATORS

tDKK					2020/21
Net revenue	245,442	226,682	191,192	110,530	71,638
Cost of goods sold	188,696	170,264	141,804	80,383	54,300
Gross profit before other external costs	56,746	56,418	49,388	30,147	17,338
Capacity costs	46,232	35,405	28,306	14,797	6,440
Operating profit before interest, tax, depreciation and amortisation (EBITDA)	10,514	21,013	21,082	15,350	10,898
Earnings before interest and tax (EBIT)	1,789	13,751	16,627	14,741	10,873
Net financial items	-1,574	-3,683	-834	-30	-333
Earnings before tax (EBT)	215	10,068	15,794	14,712	10,540
Net profit	26	7,787	12,224	11,373	8,157
Total assets	205,858	174,115	163,964	106,125	44,644
Investments in tangible fixed assets	20,807	18,469	40,820	13,757	0
Ending cash balance	2,149	10,997	459	27,763	25,401
Equity	82,665	82,483	74,451	62,186	24,110
Weighted average of outstanding shares (in 1,000 units)	27,641	27,456	27,300	26,708	3,307
Closing number of outstanding shares (in 1,000 units)	27,687	27,502	27,317	27,250	21,250
Earnings per share (DKK)	0.00	0.28	0.45	0.43	2.47
EBITDA margin (%)	4.3%	9.3%	11.0%	13.9%	15.2%
Solvency ratio (%)	40.2%	47.4%	45.4%	58.6%	54.0%

Key figures and performance indicators are defined and calculated as follows:



Solvency ratio (%) Equity * 100 / Total assets EBITDA margin (%)
EBITDA*100/ Net revenue

Capacity costs
Other external costs + staff costs



STATEMENT BY THE BOARD OF DIRECTORS & EXECUTIVE BOARD

STATEMENT BY THE BOARD OF DIRECTORS & EXECUTIVE BOARD

The Board of Directors and the Executive Board have today discussed and approved the annual report of Scandinavian Medical Solutions A/S for the financial year 1 October 2024 – 30 September 2025. The annual report has been prepared in accordance with the Danish Financial Statements Act. In our opinion, the consolidated financial statements and the parent company's financial statements give an accurate and fair view of the Group's and the Parent Company's assets, liabilities, and financial position at 30 September 2025 and of the results of the Group's and the Parent Company's operations and consolidated cash flows for the financial year 1 October 2024 – 30 September 2025. Further, in our opinion, the Management's review gives a fair review of the development in the Group's and the Parent Company's activities and financial matters, of the results for the year and of the Group's and the Parent Company's financial position. We recommend that the annual report be approved at the annual general meeting.

Aalborg, 20 November 2025

EXECUTIVE BOARD

JENS HVID PAULSEN

CEO

JENS KROHN CEO US

KAMILLA MALMBÆK CLAO

BOARD OF DIRECTORS

MILLE TRAM LUX

Chairman

ANNE BÜLOW KAPTAIN
Deputy Chairman

MORTEN RASMUSSEN

Board Member





INDEPENDENT AUDITOR'S REPORT

TO THE SHAREHOLDERS OF SCANDINAVIAN MEDICAL SOLUTIONS A/S

OPINION

We have audited the consolidated financial statements and the parent company financial statements of Scandinavian Medical Solutions A/S for the financial year 1 October – 30 September 2025 comprising income statement, balance sheet, statement of changes in equity and notes, including accounting policies, for the Group as well as for the Parent Company and a cash flow statement for the Group. The consolidated financial statements and parent company financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the consolidated financial statements and the parent company financial statements give a true and fair view of the Group's and the Parent Company's assets, liabilities and financial position at 30 September 2025 and of the results of the Group's and the Parent Company's operations and consolidated cash flows for the financial year 1 October – 30 September 2025 in accordance with the Danish Financial Statements Act.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the consolidated financial statements and the parent company financial statements" section of our report.

We are independent of the Group in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

We believe that the audit evidence we have obtained is sufficient and appropriate

to provide a basis for our opinion.

MANAGEMENT'S RESPONSIBILITY FOR THE CONSOLIDATED FINANCIAL STATE-MENTS AND THE PARENT COMPANY FINANCIAL STATEMENTS

Management is responsible for the preparation of consolidated financial statements and parent company financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control that Management determines is necessary to enable the preparation of consolidated financial statements and parent company financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements and the parent company financial statements, Management is responsible for assessing the Group's and the Parent Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the consolidated financial statements and the parent company financial statements unless Management either intends to liquidate the Group or the Company or to cease operations, or has no realistic alternative but to do so.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS AND THE PARENT COMPANY FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance as to whether the consolidated financial statements and the parent company financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of financial statement users made on the basis of these consolidated financial statements and parent company financial statements.



INDEPENDENT AUDITOR'S REPORT

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also

- identify and assess the risks of material misstatement of the consolidated financial statements and the parent company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's and the Parent Company's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the consolidated financial statements and the parent company financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's and the Parent Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements and the parent company financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group

and the Company to cease to continue as a going concern.

- evaluate the overall presentation, structure and contents of the consolidated financial statements and the parent company financial statements, including the disclosures, and whether the consolidated financial statements and the parent company financial statements represent the underlying transactions and events in a manner that gives a true and fair view.
- Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the consolidated financial statements and the Parent Company financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

STATEMENT ON THE MANAGEMENT'S REVIEW

Management is responsible for the Management's review.

Our opinion on the consolidated financial statements and the parent company financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements and the parent company financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the consolidated financial statements or the parent company financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.



INDEPENDENT AUDITOR'S REPORT

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the consolidated financial statements and the parent company financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Aalborg, 20 November 2025

KPMG

Statsautoriseret Revisionspartnerselskab CVR no. 25 57 81 98

Steffen S. Hansen

State Authorised Public Accountant mne32737



PROFIT & LOSS STATEMENT 2024/25

Netrevenue		245,442	226,682	
Cost of goods sold		-188,696	-170,264	
Other external costs		-22,468	-16,317	
Gross profit		34,278	40,101	
Staff costs	1	-23,764	-19,088	
Depreciation		-8,623	-7,262	
Other operating costs		-102	0	
Operating profit		1,789	13,751	
Income from subsidiaries		0	0	
Financial income		577	1,547	
Financial expenses		-2,151	-5,230	
Profit before tax		215	10,068	
Tax on profit for the year	2	-189	-2,281	
Net profit	3	26	7,787	

220,456	226,123
-173,369	-169,642
-18,416	-18,969
28,671	37,512
-19,539	-17,198
-8,000	-7,159
-102	0
1,030	13,155
799	179
275	1,547
-2,150	-4,882
-46	9,998
72	-2,211
26	7,787



BALANCE SHEET 2024/25

Assets tDKK			
Operating equipment and fixtures		2,665	2,570
Leasehold improvements		1,713	853
Rentalassets		44,910	37,792
Rental assets under construction		13,349	10,639
Tangible fixed assets	4	62,637	51,854
Deposits		1,411	1,110
Receivables from group entities		0	0
Equity investments in subsidiaries		0	0
Financial assets	5	1,411	1,110
Non-current assets		64,048	52,964
Trading goods		106,435	80,606
Prepayment for goods		3,302	3,974
Inventories		109,737	84,580
Trade receivables		22,717	21,163
Receivables from group entities		0	0
Incometax		964	0
Other receivables		4,392	3,007
Prepaid expenses	6	1,851	1,404
Receivables		29,924	25,574
Cash and cash equivalents		2,149	10,997
Total current assets		141,810	121,151
TOTAL ASSETS		205,858	174,115

2,004	1,876
1,571	655
41,394	37,792
9,394	10,587
54,363	50,910
1,124	810
7,671	0
945	179
9,740	989
64,103	51,899
102,808	80,319
1,883	3,974
104,691	84,293
19,142	20,823
8,242	4,880
964	0
3,714	2,609
1,509	1,203
33,571	29,515
0	8,320
138,262	122,128
202,365	174,027



BALANCE SHEET 2024/25

Share capital		1,107	1,100	
Reserve according to equity method		0	0	
Translation reserve		-89	0	
Retained earnings		81,647	81,383	
Equity		82,665	82,483	
Deferred tax provisions	2	1,825	947	
Provisions		1,825	947	
Leaseliabilities		30,342	13,351	
Non-current liabilities other than provisions	7	30,342	13,351	
Short-term lease liabilities	7	6,622	4,030	
Debt to financial institutions		26,562	21,863	
Prepayment from customers		4,583	7,705	
Trade payables		49,812	40,602	
Incometax		159	1,110	
Other liabilities		3,288	2,024	
Current liabilities other than provisions		91,026	77,334	
Total liabilities other than provisions		121,368	90,685	
TOTAL EQUITY AND LIABILITIES		205,858	174,115	
Non-reognized lease and rental liabilities	8			
Contingent liabilities	9			
Pledges and collateral	10			
Releated parties	11			

1,107	1,100			
889	179			
0	0			
80,669	81,204			
82,665	82,483			
1,825	947			
1,825	947			
30,342	13,351			
30,342	13,351			
6,622	4,030			
26,562	21,863			
3,470	7,687			
48,741	40,603			
0	1,040			
2,138	2,023			
87,533	77,246			
117,875	90,597			
202,365	174,027			



STATEMENT OF CHANGES IN EQUITY 2024/25

Equity 1 October 2024	1,100	0	81,383	82,483
Capital injection	7	0	238	245
Currency rate adjustment	0	-89	0	-89
Transferred over the profit appropriation	0	0	26	26
Equity 30 September 2025	1,107	-89	81,647	82,665

PARENT tDKK				
Equity 1 October 2024	1,100	179	81,204	82,483
Capital injection	7	0	238	245
Currency rate adjustment	0	-89	0	-89
Transferred over the profit appropriation	0	799	-773	26
Equity 30 September 2025	1,107	889	80,669	82,665



CASH FLOW STATEMENT 2024/25

Operating profit		1,789	13,751
Depreciation and Other operating costs		8,725	7,262
Change in net working capital	12	-21,155	-6,912
Cash generated from operations		-10,641	14,101
Financial income received		577	1,547
Financial expenses paid		-2,151	-5,230
Paid tax		-1,198	-7,025
Cash flow from operating activities		-13,413	3,392
Purchase of tangible fixed assets		-20,807	-18,469
Sale of tangible fixed assets		1,277	7,643
Addition of financial assets		-314	-300
Cash flow from investing activities		-19,844	-11,126
Free cash flow generated by operations and investments before financing		-33.257	-7.734



CASH FLOW STATEMENT 2024/25

Capital increase		245	244		
Proceeds from new debt to financial institutions		4,892	21,671		
Proceeds from new leasing debt		33,143	0		
Repayments leasing debt		-13,559	-3,763		
Cash flow from financing activites		24,721	18,152		
Change in cash and cash equivalents		-8,536	10,418		
Cash and cash equivalents beginning of year		10,806	459		
Foreign currency adjustment		-121	-71		
Cash and cash equivalents end of year		2,149	10,806		
Cash and cash equivalents		2,149	10,997		
Short-term bank debt		0	-191		
Cash and cash equivalents end of year		2,149	10,806		



1. STAFF COSTS

tDKK				
Wages and salaries	21,186	16,645	16,961	14,719
Pension (defined contribution)	2,352	2,158	2,352	2,158
Other costs social security	226	285	226	321
	23,764	19,088	19,539	17,198
Average number of full-time employees	29	26	26	26
Remuneration of the Executive Board and the Board of Directors				
Executive Board including 10% pension			5,621	5,191
Board of Directors			588	700
			6,209	5,891

Salary compensation are off set in the wages and salary with 126 tDKK (2023/24: 183 tDKK)

Outstanding warrants 1 October 2024	237,334	66,667
Exercised in 2024/25	-118,666	-66,667
Outstanding warrants per 30 September 2025	118,668	0
Strike price	1.5 DKK	1 DKK
Residual exercising period	25 months	13 months

Share options has been granted in accordance with clause 4.6 in the company articles of association. The specifics of the program can be found in appendix 1 to the articles of association.

556,000 warrants, equal to 2% of all shares, has been granted exclusively to the sales organization in two separate programs during the on-boarding process for the sales employees.

The warrants will vest in 3 portions and can be exercised over 4 year from the beginning of each program. At the end of 2024/25 all vested warrants was exercised.

Further programs have not been addressed by the board.



2. TAX


tDKK				
Current tax	253	1,151	0	1,081
Prior year adjustment	-942	-52	-950	-52
Adjustment of deferred tax including adjustment prior year	878	1,182	878	1,182
	189	2,281	-72	2,211

Deferred tax tDKK				
Deferred tax at beginning of period	-947	235	-947	235
Adjustment of deferred tax for the year	-878	-1,182	-878	-1,182
Deferred tax at end of the period	-1,825	-947	-1,825	-947

Deferred tax includes tangible fixed assets, leasing debt and value of tax losses carried forward.

3. NET PROFIT

tDKK				
Retained earnings	26	7,787	-773	7,608
Allocated to reserve according to equity method	0	0	799	179
	26	7,787	26	7,787





4. TANGIBLE FIXED ASSETS

		GROUP			
Cost price beginning of year	3,165	1,282	46,457	10,639	
Currency adjustments	-36	-9	0	-2	
Additions	935	1,161	7,578	11,133	
Transferred	0	0	8,421	-8,421	
Disposals	0	0	-2,288	0	
Cost price end of year	4,064	2,434	60,168	13,349	
Depreciation beginning of year	595	429	8,665	0	
Currency adjustments	-16	-2	-8	0	
Depreciation for the year	820	294	7,509	0	
Depreciation on disposals	0	0	-908	0	
Depreciation end of year	1,399	721	15,258	0	
Carrying amount end of year	2,665	1,713	44,910	13,349	
Of which, leased assets			37,243		

2,371	1,080	46,457	10,587
0	0	0	0
757	1,170	6,759	7,228
0	0	8,421	-8,421
0	0	-5,780	0
3,128	2,250	55,857	9,394
495	426	8,665	0
0	0	0	0
629	253	7,118	0
0	0	-1,320	0
1,124	679	14,463	0
2,004	1,571	41,394	9,394
		37,243	



5. FINANCIAL ASSETS

tDKK			
Cost beginning of year	1,110	810	0
Currency adjustments	-13	0	0
Additions	314	314	7,671
Cost per end of year	1,411	1,124	7,671
Carrying amount end of year	1,411	1,124	7,671

tDKK	
Cost per beginning of year	0
Additions	56
Cost per end of year	56
Revaluations per beginning of year	179
Profil/loss for the year	799
Currency adjustments	-89
Revaluation at end year	889
Carrying amount end of year	945

Scandinavian Medical Solutions Inc.	Santa Ana, USA	100%
Scandinavian Medical Solutions Sarl.	Paris, France	100%

6. PREPAID EXPENSES

Prepaid expenses consists of prepaid insurances, licenses etc.

7. NON-CURRENT LIABILITIES

Lease liabilities amount to DKK 36,964 thousand, of which DKK 7,815 thousand is due after five years.

8. NON-RECOGNIZED LEASE & RENTAL LIABILITIES

Parent company

The parent company has entered into operating leasing agreements with a contractual obligation of DKK 176 thousand. Of the contractual obligation, DKK 176 thousand falls due within 1 year from the balance sheet date.

The parent company has entered into rent obligations with a contractual obligation of DKK 1,087 thousand. Of the contractual obligation, DKK 1,049 thousand falls due within 1 year from the balance sheet date.

Group

The group has entered into operating leasing agreements with a contractual obligation of DKK 176 thousand. Of the contractual obligation, DKK 176 thousand falls due within 1 year from the balance sheet date.

The group has entered into rent obligations with a contractual obligation of 2,680 thousand. Of the contractual obligation, DKK 1,929 thousand falls due within 1 year from the balance sheet date.



9. CONTINGENT LIABILITIES

The Group was, until 21 November 2022, jointly taxed with all Danish-affiliated companies, but is hereafter independently taxed due to changes in the ownership structure. The Danish entities were jointly and severally liable for tax on the Group's jointly taxed income until the end of the joint taxation. The jointly taxed entities' total net liability to SKAT amounted to DKK 0 thousand on 30 September 2025. Any subsequent corrections of the taxable income subject to joint taxation or withholding taxes on dividends, etc., may increase the entities' liability. The Group is not liable to any other parties.

10. PLEDGES & COLLATERAL

Parent

As collateral towards financial institutions with a net liability DKK 26,562 thousand as of 30 September 2025, there is placed a company pledge of DKK 1,500 thousand and DKK 14,000 thousand with collaterals in operating equipment and fixtures, leasehold improvements, rental assets, inventories, and trade receivables. The carrying value of pledged assets amount to DKK 153,659 thousand as of 30 September 2025. Rental assets financed under finance lease with a carrying amount of DKK 37,243 thousand are pledged towards the leasing company with leasing liabilities of DKK 36,964 thousand as of 30 September 2025.

Group

As collateral towards financial institutions with a liability of DKK 26,562 thousand as of 30 September 2025, there is placed a company pledge of DKK 1,500 thousand and DKK 14,000 thousand with collaterals in operating equipment and fixtures, leasehold improvements, rental assets, inventories, and trade receivables. The carrying value of pledged assets amount to DKK 151,706 thousand as of 30 September 2025. Rental assets financed under finance lease with a carrying amount of DKK 37,243 thousand are pledged towards the leasing company with leasing liabilities of DKK 36,965 thousand as of 30 September 2025.

11. RELATED PARTIES

Related parties comprise the Board of Directors, Executive Board, their close family members and companies.

No owners have exercising control.

Through holding companies CEO Jens Krohn has an ownership stake of 35.03% of the company and thereby significant influence.

The following transactions with related parties occurred during the financial year (all amounts in tDKK)

Sale of goods to group entities	16.386
Purchase of services from associates	169

Remunertation for management and board is disclosed in note 1 Intercompany receivable is shown in balance sheet for parent company

12. CHANGE IN NET WORKING CAPITAL

Change, Inventories	-25,157	1,346
Change, Receivables	-3,386	-4,555
Change, Trade payables	9,210	6,920
Change, Other payables	-1,699	-10,624
Currency adjustments	-123	1
	-21,155	-6,912



The annual report has been prepared in accordance with Danish financial statements legislation and generally accepted accounting principles. It has also been prepared in accordance with the provisions applying to reporting class C medium-sized entities under the Danish Financial Statements Act. These policies have been consistently applied throughout the years.

RECLASSIFICATION

Referring to the true and fair view set out in the Danish Financial Statements Act, the Company has reclassified individual items in the income statement. The reclassifications have affected the items Cost of goods sold, Other external costs and Staff costs but have not affected results before tax, results for the year or equity. Comparative figures have been restated accordingly.

RECOGNITION & MEASUREMENT

Assets are recognized in the balance sheet when, because of a past event, it is probable that future economic benefits will flow to the company and when the asset's value can be reliably measured. Liabilities are recognized in the balance sheet when, because of a past event, the company has a legal or actual obligation, and it is probable that future financial benefits will flow from the company. The value of the obligation can be measured reliably. On initial recognition, assets and liabilities are measured at cost price. Measurement after initial recognition is done as described for each accounting item below. On recognition and measurement, anticipated losses and risks that appear before the annual report's presentation and confirm or invalidate conditions existing at the balance sheet date are considered. The income is recognized in the income statement as earned. Furthermore, all costs incurred to earn the profit for the year have been recognized in the income statement.

FOREIGN CURRENCY TRANSLATION

The Company uses DKK as its functional and presentation currency. Transactions in foreign currency will be translated upon initial recognition at the exchange rate on the day of the transaction. Receivables, liabilities, and other monetary items in foreign currency that have not been settled on the balance sheet date are converted at the balance sheet date's exchange rate. Exchange rate differences that

arise between the exchange rate on the day of the transaction and the exchange rate on the payment date and the balance sheet date are recognized in the income statement as financial items. Tangible and intangible fixed assets, inventories, and other non-monetary assets purchased in foreign currency are converted at historical rates

NET REVENUE

The income statement recognizes net revenue from selling parts and equipment when delivery and risk transfer to the buyer has occurred. The date of transfer of the most significant benefits and risks is determined using standard Incoterms ©2020. The point of revenue recognition is when the agreed delivery obligations are met

Lease income from rental assets and income from service contracts is recognized in the income statement ratably over the term of the agreements.

Net revenue is recognized excluding VAT, taxes, and discounts in connection with the sale and is measured at the fair value of the fixed consideration.

COST OF GOODS SOLD

The cost of goods sold includes the financial years' sales, which are measured at cost price and adjusted for usual inventory write-downs.

OTHER EXTERNAL COSTS

Other external costs include costs related to the company's primary activities, including premises, office maintenance, sales, promotion, etc.

STAFF COSTS

Staff costs include wages, salaries, social security, pensions, etc., for the company's employees. Received refunds are off set in salary costs and disclosed in note.



WARRANTS

Warrants granted free of charge to the Company's employees, management, and board of directors are considered transactions among shareholders. They are, therefore, not recognized in the financial statements when granted. When warrants are exercised, the proceeds are recognized in equity as capital contribution.

INCOME FROM EQUITY INVESTMENTS IN SUBSIDIARIES

The proportionate share of the individual subsidiaries' profit/loss after tax is recognised in the Parent Company's income statement after full elimination of intra-group gains/losses and amortisation of goodwill.

FINANCIAL INCOME

Financial income consists of interest income, including net exchange rate gains relating to transactions in foreign currency.

FINANCIAL EXPENSES

Financial expenses consist of interest costs, including interest related to financial leases, net exchange rate losses relating to transactions in foreign currency and additional interest costs.

TAX

The financial year's tax, which consists of the year's current tax and changes to deferred tax, is recognized in the income statement with the part that can be attributed to the financial year's result and directly in equity with the part that can be attributed to entries directly in the equity. Until 21 November 2022, the company was jointly taxed with all Danish-affiliated companies but is hereafter independently taxed. The current Danish corporation tax in the joint taxation period is distributed between the jointly taxed companies in proportion to their taxable income (full distribution with refund regarding tax losses). Joint tax contributions between the jointly taxed companies that have not been settled at the balance sheet date are classified as joint tax contributions in receivables or liabilities.

TANGIBLE FIXED ASSETS

Tangible fixed assets are measured at cost price with accumulated depreciation

and write-down deductions.

The cost price includes the acquisition price, costs directly associated with the acquisition, and costs for preparing the asset until the asset is ready to be used.

Tangible fixed assets under construction are recognized and measured at cost at the balance sheet date. When the asset is available for use, the cost is transferred to the relevant class of assets, and depreciation begins.

The depreciation basis is cost price with a deduction of expected residual value after the end of the useful life. Straight-line depreciation is carried out based on the following assessment of the assets' expected valuable lives:

Operating equipment and fixtures 3-5 years Leasehold improvements 5 - 7 years Rental assets 4 - 10 years

Estimated useful lives and residual values are reassessed annually. Changes are treated as accounting estimates, and the effect on depreciation is recognized prospectively.

Rental assets that cease to be rented and are available for sale to others during the ordinary business are transferred to inventories at their carrying amount when they become held for sale. Proceeds from the sale of such assets are recognized as revenue.

Gains and losses on the disposal of other tangible assets are determined as the difference between the net disposal proceeds and the carrying amount of the item at the date of disposal. Gains and losses are recognized in the income statement as other operating income or other operating costs, respectively.

LEASES

On initial recognition, leases of tangible assets with the Company as lessee that transfer substantially all risks and rewards incident to ownership to the Company



(finance leases) are recognized in the balance sheet at the lower fair value and the net present value of future lease payments. When the net present value is calculated, the interest rate implicit in the lease or the incremental borrowing rate is used as the discount factor. Assets held under finance leases are subsequently depreciated as the Company's other fixed assets. The capitalized lease obligation is recognized in the balance sheet as a liability at amortized cost, allowing the interest element of the lease payment to be recognized in the income statement over the lease term. All other leases are operating leases. Payments relating to operating and other leases are recognized in the income statement over the lease term. The Company's total obligation relating to operating and other leases is disclosed as contractual obligations, contingencies, etc. Sale-and-finance-leaseback transactions are recognized as financing transactions with security in the underlying asset, which is not derecognized. The finance lease liability is recognized at the received net proceeds and measured at amortized cost. For leasing contracts for rental assets with the Company as a lessor, it is determined at initial recognition whether the contract is a finance or an operating lease. Finance leases are recognized as a sale of the underlying asset. For operating leases, the underlying asset is presented as rental assets, and rental income is recognized straight-line over the rental period.

FINANCIAL ASSETS

Lease deposits are measured at amortised cost price. Equity investments in subsidiaries are measured at the proportionate share of the entities' net asset value calculated in accordance with the Parent Company's accounting policies plus or minus unrealised intra-group gains or losses and plus or minus the residual value of positive and negative goodwill calculated in accordance with the acquisition method. Equity investments in subsidiaries with negative net asset values are measured at DKK 0, and any receivables from these entities are written down to the extent that the receivables are deemed irrecoverable. To the extent that the Parent Company has a legal or constructive obligation to cover a negative balance exceeding the receivable, the residual amount is recognised as provisions.

Part of receivable from subsidiary is long term and therefore presented as non-current financial asset in addition to investment

IMPAIRMENT OF FIXED ASSETS

The carrying amount of property, plant and equipment as well as equity investments in subsidiaries and other financial assets is subject to an annual test for indications of impairment other than the decrease in value reflected by depreciation.

Impairment tests are conducted of individual assets or groups of assets when there is an indication that they may be impaired. Write-down is made to the recoverable amount if this is lower than the carrying amount.

The recoverable amount is the higher of an asset's net selling price and its value in use. The value in use is determined as the present value of the forecast net cash flows from the use of the asset or the group of assets, including forecast net cash flows from the disposal of the asset or the group of assets after the end of the useful life.

Previously recognized write-downs are reversed when the basis for the write-down no longer exists.

INVENTORY

Inventory and prepayments for goods are measured at cost price or net realizable value if this is lower. The cost price includes the acquisition price with the addition of purchase costs, helium, delivery costs, and packaging materials. The net realizable value of inventories is calculated as the sales amount minus costs of completion and costs necessary to make the sale. It is determined considering marketability, obsolescence, and development in expected selling price.

RECEIVABLES

Receivables are measured at amortized cost price, which usually corresponds to nominal value, with a deduction of write-downs to cover expected losses.

DEFERRED TAX

Deferred tax is measured according to the liability method. Provision has been made for deferred tax by statutory rate on all temporary differences between the carrying amount and tax-based value of assets and liabilities. Deferred tax is also



measured for the planned use of the asset and the settlement of the liability.

PREPAYMENTS

Prepayments comprise prepayments of costs incurred relating to subsequent financial years.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash deposits.

EQUITY

Net revaluation reserve according to the equity method comprises net revaluation of equity investments in subsidiaries and participating interests (including associates) in proportion to cost. Dividends that are expected to be received before the balance sheet date are not tied to the reserve. The reserve can be eliminated in case of loss, realisation of equity investments or changes to accounting estimates. The reserve cannot be recognised at a negative amount.

The translation reserve comprises the share of foreign exchange differences arising on translation of financial statements of entities that have a functional currency other than DKK, foreign exchange adjustments of assets and liabilities considered part of the Company's net investments in such entities and foreign exchange adjustments regarding hedging transactions that hedge the Company's net investments in such entities. The reserve is dissolved on the sale of foreign entities or if the conditions for effective hedging no longer exist. When equity investments in group entities and participating interests in the parent company financial statements are subject to the limitation requirement in the net revaluation reserve according to the equity method, foreign exchange adjustments will be included in this equity reserve instead.

PREPAYMENTS FROM CUSTOMERS

Customer prepayments received from customers include amounts received from customers prior to the time of delivery.

OTHER LIABILITIES

Other liabilities are measured at amortized cost, which typically corresponds to nominal value.

CASH FLOW STATEMENT

The cash flow statement shows cash flows relating to operations, investments, and financing, as well as cash and cash equivalents at the beginning and end of the year. Cash flows relating to operating activities are presented using the indirect method.

They are calculated as the operating result adjusted for non-cash operating items, change in working capital, paid financial income, financial expenses, and corporation tax. Cash flows relating to investment activities include payments concerning the purchase and sale of non-current assets. Cash flows relating to financing activities include changes in the size or composition of the company's capital and the costs associated with this, as well as the taking out of loans, repayment of interest-bearing debt, leasing debt, purchase of treasury shares, and payment of dividends. Cash and cash equivalents include cashholdings, fewer overdraft facilities when they are repayable on demand, form an integral part of the Company's cash management, and frequently fluctuate from positive to overdrawn.

